Inside Tevogen's $50M expansion push and the team picked to run it

Tevogen (Nasdaq: TVGN) has appointed interim leaders across five core verticals to execute its diversified growth strategy, targeting potential acquisitions expected to generate over $50 million in annual revenues. These transactions are anticipated to close by Q2 2026, though they are subject to customary due diligence and definitive agreements. The company aims to broaden its portfolio into digital health, generics, contract research, biotech, and AI, reflecting its mission to advance innovation and patient access.